On February 1, 2017, the Federal Court dismissed Apotex’s application for judicial review of the Minister of Health’s refusal to approve its Abbreviated New Drug Submission (ANDS) for Apo-Progesterone: Apotex Inc v Canada (Health)2017 FC 127. The Court found no breach of procedural fairness, and concluded that the Minister’s decision to refuse to approve the ANDS on the basis that the drug product contained unusually high levels of sodium lauryl sulfate (SLS) was reasonable. That the U.S. Food and Drug Administration had previously approved a different drug product with higher levels of SLS did not render the decision unreasonable.